The Manufacturers Life Insurance Company Acquires 254,205 Shares of Abbott Laboratories $ABT

The Manufacturers Life Insurance Company raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,370,397 shares of the healthcare product maker’s stock after purchasing an additional 254,205 shares during the period. The Manufacturers Life Insurance Company’s holdings in Abbott Laboratories were worth $487,310,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ABT. Capstone Financial Advisors Inc. boosted its stake in Abbott Laboratories by 10.6% during the 2nd quarter. Capstone Financial Advisors Inc. now owns 3,300 shares of the healthcare product maker’s stock valued at $299,000 after purchasing an additional 316 shares during the last quarter. Archford Capital Strategies LLC grew its position in shares of Abbott Laboratories by 17.2% during the 2nd quarter. Archford Capital Strategies LLC now owns 2,715 shares of the healthcare product maker’s stock valued at $246,000 after acquiring an additional 398 shares during the period. National Pension Service increased its stake in shares of Abbott Laboratories by 2.8% in the 2nd quarter. National Pension Service now owns 4,208,467 shares of the healthcare product maker’s stock worth $381,876,000 after purchasing an additional 114,105 shares in the last quarter. Krensavage Asset Management LLC raised its stake in shares of Abbott Laboratories by 3,900.0% in the second quarter. Krensavage Asset Management LLC now owns 200,000 shares of the healthcare product maker’s stock worth $18,148,000 after buying an additional 195,000 shares during the period. Finally, Plimoth Trust Co. LLC raised its position in shares of Abbott Laboratories by 2.8% during the 2nd quarter. Plimoth Trust Co. LLC now owns 28,195 shares of the healthcare product maker’s stock valued at $2,558,000 after purchasing an additional 768 shares during the period. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research analyst reports. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Bank of America dropped their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. BTIG Research raised their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Stock Down 1.8%

ABT stock opened at $103.37 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a 50-day simple moving average of $105.46 and a 200-day simple moving average of $99.84. The stock has a market capitalization of $178.87 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.95 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.